The meeting will be held July 11-12, 2016 in Bethesda, MD.
Goals and Objectives
- To provide a forum for open discussion between scientists from academia, government, and the pharmaceutical industry on pulmonary vascular disease and the novel therapies being developed to treat it.
- To discuss the safety and efficacy data for these therapies and the level of data needed to support their approval.
Who Should Attend
This annual meeting is intended for scientists from academia, government, and industry responsible for developing and regulating products for the treatment of pulmonary hypertension as well as those parties responsibly for the treatment of these patients.
The primary audience includes leading academic experts, interested pharmaceutical companies, regulatory agencies, patient advocacy groups, non-profit organizations, scientists, patient representatives, and healthcare providers who work in this therapeutic area.
Phone: (240) 402-2170